6.7(top 2%)
Impact Factor
7.2(top 2%)
extended IF
134(top 2%)
H-Index
3.5K
authors
4K
papers
126.1K
citations
5.6K
citing journals
51.8K
citing authors

Most Cited Articles of Diabetes, Obesity and Metabolism

TitleYearCitations
Pancreatic beta-cell mass in European subjects with type 2 diabetes2008564
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial2007535
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes2013501
Adiponectin--a key adipokine in the metabolic syndrome2006468
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise2013460
Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c2010443
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin2007437
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors2012384
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease2013376
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review2011367
Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women2006363
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes2006360
Insulin-associated weight gain in diabetes--causes, effects and coping strategies2007351
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia2012342
Role of vitamin D in the pathogenesis of type 2 diabetes mellitus2008333
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin2014321
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes2012303
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial2011302
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes2015289
Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity2007289
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial2014273
Advanced glycation endproducts: what is their relevance to diabetic complications?2007272
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes2010262
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials2013259
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial2011259